Skip to main content
OTCMKTS:TCNNF

Trulieve Cannabis Competitors

$39.35
+0.41 (+1.05 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.75
$39.76
50-Day Range
$35.43
$49.08
52-Week Range
$11.11
$53.73
Volume211,900 shs
Average Volume454,166 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Trulieve Cannabis (OTCMKTS:TCNNF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying TCNNF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Trulieve Cannabis, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Trulieve Cannabis (OTCMKTS:TCNNF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Trulieve Cannabis and Abacus Health Products' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trulieve CannabisN/AN/AN/AN/AN/A
Abacus Health ProductsN/AN/AN/AN/AN/A

Profitability

This table compares Trulieve Cannabis and Abacus Health Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trulieve CannabisN/AN/AN/A
Abacus Health ProductsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Trulieve Cannabis and Abacus Health Products, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trulieve Cannabis001103.00
Abacus Health Products0000N/A

Trulieve Cannabis currently has a consensus price target of $65.6389, suggesting a potential upside of 66.82%. Given Trulieve Cannabis' higher possible upside, equities research analysts plainly believe Trulieve Cannabis is more favorable than Abacus Health Products.

Summary

Trulieve Cannabis beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Trulieve Cannabis (OTCMKTS:TCNNF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Trulieve Cannabis and Acreage's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trulieve CannabisN/AN/AN/AN/AN/A
AcreageN/AN/AN/AN/AN/A

Profitability

This table compares Trulieve Cannabis and Acreage's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trulieve CannabisN/AN/AN/A
AcreageN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Trulieve Cannabis and Acreage, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trulieve Cannabis001103.00
Acreage01202.67

Trulieve Cannabis currently has a consensus price target of $65.6389, suggesting a potential upside of 66.82%. Acreage has a consensus price target of $8.4333, suggesting a potential upside of 204.45%. Given Acreage's higher possible upside, analysts plainly believe Acreage is more favorable than Trulieve Cannabis.

Summary

Trulieve Cannabis beats Acreage on 2 of the 3 factors compared between the two stocks.

Trulieve Cannabis (OTCMKTS:TCNNF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Trulieve Cannabis and Applied Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trulieve CannabisN/AN/AN/AN/AN/A
Applied BiosciencesN/AN/AN/AN/AN/A

Profitability

This table compares Trulieve Cannabis and Applied Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trulieve CannabisN/AN/AN/A
Applied BiosciencesN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Trulieve Cannabis and Applied Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trulieve Cannabis001103.00
Applied Biosciences0000N/A

Trulieve Cannabis currently has a consensus price target of $65.6389, suggesting a potential upside of 66.82%. Given Trulieve Cannabis' higher possible upside, equities research analysts plainly believe Trulieve Cannabis is more favorable than Applied Biosciences.

Summary

Trulieve Cannabis beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Trulieve Cannabis (OTCMKTS:TCNNF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Trulieve Cannabis and Ayr Strategies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trulieve CannabisN/AN/AN/AN/AN/A
Ayr StrategiesN/AN/AN/AN/AN/A

Profitability

This table compares Trulieve Cannabis and Ayr Strategies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trulieve CannabisN/AN/AN/A
Ayr StrategiesN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Trulieve Cannabis and Ayr Strategies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trulieve Cannabis001103.00
Ayr Strategies01602.86

Trulieve Cannabis currently has a consensus price target of $65.6389, suggesting a potential upside of 66.82%. Ayr Strategies has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Trulieve Cannabis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Trulieve Cannabis is more favorable than Ayr Strategies.

Summary

Trulieve Cannabis beats Ayr Strategies on 3 of the 3 factors compared between the two stocks.

Trulieve Cannabis (OTCMKTS:TCNNF) and Can B (NASDAQ:CANB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Trulieve Cannabis and Can B's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trulieve CannabisN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A

Profitability

This table compares Trulieve Cannabis and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trulieve CannabisN/AN/AN/A
Can BN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Trulieve Cannabis and Can B, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trulieve Cannabis001103.00
Can B0000N/A

Trulieve Cannabis currently has a consensus price target of $65.6389, suggesting a potential upside of 66.82%. Given Trulieve Cannabis' higher possible upside, equities research analysts plainly believe Trulieve Cannabis is more favorable than Can B.

Summary

Trulieve Cannabis beats Can B on 2 of the 2 factors compared between the two stocks.

Trulieve Cannabis (OTCMKTS:TCNNF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares Trulieve Cannabis and Cansortium's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trulieve CannabisN/AN/AN/AN/AN/A
CansortiumN/AN/AN/AN/AN/A

Profitability

This table compares Trulieve Cannabis and Cansortium's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trulieve CannabisN/AN/AN/A
CansortiumN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Trulieve Cannabis and Cansortium, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trulieve Cannabis001103.00
Cansortium00103.00

Trulieve Cannabis currently has a consensus price target of $65.6389, suggesting a potential upside of 66.82%. Cansortium has a consensus price target of $1.20, suggesting a potential upside of 23.71%. Given Trulieve Cannabis' higher possible upside, equities research analysts plainly believe Trulieve Cannabis is more favorable than Cansortium.

Summary

Trulieve Cannabis beats Cansortium on 2 of the 2 factors compared between the two stocks.


Trulieve Cannabis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84+5.4%$0.00N/A0.00News Coverage
Gap Down
Acreage logo
ACRGF
Acreage
1.2$2.77+0.0%$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.08+0.0%$0.00N/A0.00
AYRSF
Ayr Strategies
1.4$21.26+0.0%$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.39+2.6%$0.00N/A0.00Gap Down
Cansortium logo
CNTMF
Cansortium
0.9$0.97+5.2%$0.00N/A0.00Gap Down
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$3.27+0.3%$0.00N/A0.00Earnings Announcement
Analyst Report
Gap Up
Choom logo
CHOOF
Choom
0.5$0.07+0.0%$0.00N/A0.00Gap Up
CPHRF
Cipher Pharmaceuticals
1.2$1.15+2.6%$0.00N/A0.00
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.5$0.19+0.0%$0.00N/A0.00Gap Up
Cosmos logo
COSM
Cosmos
0.5$6.60+9.2%$0.00N/A0.00News Coverage
Gap Down
Cresco Labs logo
CRLBF
Cresco Labs
1.3$11.82+3.6%$0.00N/A0.00Gap Down
Curaleaf logo
CURLF
Curaleaf
1.6$14.40+4.6%$0.00N/A0.00Gap Down
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00+0.0%$0.00N/A0.00News Coverage
Gap Up
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.12+8.3%$0.00N/A0.00Gap Down
EVIO logo
EVIO
EVIO
0.6$0.00+5.3%$0.00N/A0.00Gap Down
Flower One logo
FLOOF
Flower One
0.4$0.22+0.0%$0.00N/A0.00Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05+0.0%$0.00N/A0.00Gap Up
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01+0.0%$0.00N/A0.00News Coverage
Gap Down
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$29.50+3.4%$0.00N/A0.00Analyst Report
News Coverage
GTEC logo
GGTTF
GTEC
0.6$0.48+2.1%$0.00N/A0.00News Coverage
Gap Down
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$4.25+2.6%$0.00N/A0.00Upcoming Earnings
Analyst Report
Gap Down
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01+0.0%$0.00N/A0.00Gap Down
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00News Coverage
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$67.89+0.0%$0.00N/A0.00
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.18+0.0%$0.00N/A0.00Gap Down
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.26+7.8%$0.00N/A0.00Gap Down
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04+0.0%$0.00N/A0.00Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.07+30.6%$0.00N/A0.00Gap Up
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.40+5.1%$0.00N/A0.00Gap Down
Knight Therapeutics logo
KHTRF
Knight Therapeutics
1.2$4.41+2.3%$0.00N/A0.00News Coverage
Gap Up
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01+0.0%$0.00N/A0.00News Coverage
Gap Down
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.04+0.0%$0.00N/A0.00
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.34+3.0%$0.00N/A0.00
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.32+3.1%$0.00N/A0.00Gap Down
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$34.21+2.1%$0.00N/A0.00Analyst Report
News Coverage
MJardin Group logo
MJARF
MJardin Group
1.1$0.05+17.2%$0.00N/A0.00Gap Up
MYHI
Mountain High Acquisitions
0.5$0.02+0.0%$0.00N/A0.00Gap Down
PHCEF
Pharmacielo
0.7$1.35+8.9%$0.00N/A0.00Gap Down
Plus Products logo
PLPRF
Plus Products
1.1$0.41+0.0%$0.00N/A0.00Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00+0.0%$0.00N/A0.00Gap Down
PCYN
Procyon
0.4$0.60+0.0%$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01+14.5%$0.00N/A0.00Gap Down
SANP
Santo Mining
0.5$0.00+0.0%$0.00N/A0.00
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.19+0.8%$0.00N/A0.00Gap Up
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40+0.0%$0.00N/A0.00News Coverage
TerrAscend logo
TRSSF
TerrAscend
1.7$11.33+1.3%$0.00N/A0.00Gap Down
The Flowr logo
FLWPF
The Flowr
1.5$0.20+0.0%$0.00N/A0.00
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.